Sign in

You're signed outSign in or to get full access.

Vivian

Managing Director at BTIG

Vivian Cervantes is a Managing Director at Gilmartin Group, specializing in investor relations advisory for the healthcare and life sciences sectors, with a focus on biotech and healthcare technology companies. She has extensive experience guiding clients through private and public financing transactions, IPOs, and M&A communications, working closely with industry leaders and innovators across the sector. Prior to joining Gilmartin Group in 2022, Vivian held roles at investment banks including BTIG, where she built relationships with both buy-side and sell-side stakeholders. She holds FINRA Series 7 and 63 licenses, and her expertise is recognized through frequent invitations to moderate panels on liquidity, capital markets, and industry strategy.

Vivian's questions to NEOGENOMICS (NEO) leadership

Question · Q3 2025

Vivian asked for clarification on the specific indications NeoGenomics is pursuing for RaDaR ST beyond the currently approved head and neck and breast cancers, and the expected cadence of reimbursement and further milestones for 2026.

Answer

CEO Tony Zook confirmed current indications as HPV negative adjuvant surveillance in head and neck and HR positive/HER2 negative surveillance five years out in breast cancer. He stated intentions for additional indication submissions for RaDaR ST, without specifying them, and highlighted the ongoing next-gen MRD program for ultra-sensitive options in low-shedding cancers. Tony Zook expects these new indication submissions to manifest in the second half of 2026, avoiding redundancy with the next-gen program.

Ask follow-up questions

Fintool

Fintool can predict NEOGENOMICS logo NEO's earnings beat/miss a week before the call

Question · Q3 2025

Vivian asked for a reminder of the indications NeoGenomics is pursuing for Radar ST beyond head and neck and breast cancer. She also inquired about the expected cadence of reimbursement for these indications and any further milestones to look for in 2026.

Answer

CEO Tony Zook confirmed the two current indications are subsets of HPV-negative adjuvant surveillance in head and neck cancer and HR-positive, HER2-negative surveillance five years out in breast cancer. He stated the company plans additional submissions for indication expansion for Radar ST, without specifying for competitive reasons. He also mentioned the ongoing next-gen MRD program, which aims for ultra-sensitive options for low-shedding cancers, with new indication submissions expected in the short term and potential manifestation in H2 2026.

Ask follow-up questions

Fintool

Fintool can write a report on NEOGENOMICS logo NEO's next earnings in your company's style and formatting